Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

ALTHOUGH UPDATED OVERALL survival (OS) findings from KEYNOTE-564 (NCT03142334) demonstrated continued benefit in patients with clear cell renal cell carcinoma (ccRCC) who received adjuvant ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II ... Imfinzi, in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinzi ...

Yohann Loriot explored rechallenge with the same class of agents in advanced urothelial and renal cell carcinomas ... A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by ...

In the Durvalumab arm, patients were randomized to receive Durvalumab with Gemcitabine + Cisplatin (GC) for 4 cycles, followed by RC and adjuvant Durvalumab for up to 8 cycles. In the comparator arm, ...

Background: Patients with locally advanced renal cell carcinoma (RCC) may experience recurrence after surgery. In the phase 3 KEYNOTE-564 (NCT03142334) trial, adjuvant pembrolizumab demonstrated ...

Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress. The BR.31 trial found that adjuvant durvalumab did not ...